Clinical Studies Tiaoshen Dingxuan Soup Joint Betahistine Mesilate Tablets For Cervcal Spondylosis Of Vertebral Artery Type (Blood Deficiency Type)

Purpose:Observe Tiaoshen Dingxuan soup joint betahistine mesilate tablets for cervcal spondylosis of vertebral artery type (blood deficiency type),through scientific statistical analysis, objective evaluation of its effectiveness and safety, and to explore its therapeutic mechanism as for cervical vertebral artery Chinese medicine treatment of disease, to provide theoretical and practical basis.Methods:A randomized controlled clinical trials met the inclusion criteria of90patients, according to the group, the order number, the random number table into Tiaoshen Dingxuan soup group (TCM group) and betahistine mesilate tablets group (Western medicine group) and Tiaoshen Dingxuan soup joint betahistine mesilate tablets group (Combined group), each with30cases, a course of two weeks. Before and after treatment one week and two weeks after treatment for three groups of patients in clinical symptom score and transcranial Doppler (TCD) observed indicators (bilateral vertebral artery and arterial base Vs, Vd, Vm value), statistical analysis and evaluation of curative effect.Results:1. After a week of treatment, the clinical symptoms and signs integral with three groups of patients before treatment difference was statistically significant (P<0.05); group among the three groups, the difference was not statistically significant (P>0.05); three patients in group TCD were observed before and after treatment the improvement was no significant difference (P>0.05); 2. After two weeks of treatment, compare three groups of patients before clinical symptoms and signs and treatment integral significant (P<0.05); which, TCM group and Western medicine group difference was statistically significant (P<0.05), TCM group and Combined group difference was statistically significant (P<0.05), The Western medicine group and the Combined group difference was statistically significant (P<0.05).Three groups of patients with TCD indicators was observed compared with before treatment difference was statistically significant (P<0.05); Among them, The TCM group, there was no statistically significant difference compared with the Western medicine group (P>0.05),TCM group and Combined group difference was statistically significant (P<0.05), The Western medicine group and the Combined group difference was statistically significant (P<0.05).3. The three groups of patients after the treatment the clinical curative effect comparison,TCM group6cases cured,8cases were markedly effective, effective in10cases,6no effect, the effective rate was80.00%; Western medicine group of4cases were cured,7cases were markedly effective, effective in11cases,8no effect, the effective rate was73.33%; Combined group cured7cases,10cases were markedly effective, effective10cases,3cases were invalid, the effective rate was90.00%. which, TCM group and Western medicine group difference was statistically significant (P<0.05), TCM group and Combined group difference was statistically significant (P<0.05), The Western medicine group and the Combined group difference was statistically significant (P<0.05). Three groups of patients during treatment no obvious adverse reaction and allergic phenomenon.Conclusion:1.Tiaoshen Dingxuan soup and betahistine mesilate tablets can effectively improve the clinical symptoms of the cervcal spondylosis of vertebral artery type spondylosis, and improve the quality of their daily lives, a significant effect;2. When improving cervcal spondylosis of vertebral artery type (blood deficiency type),in patients with clinical symptoms and signs, Tiaoshen Dingxuan soup better than betahistine mesilate tablets, TCD in improving bilateral vertebral artery and arterial base of VP, Vm value both quite effective. The combined use of treatment effect is better than that of both single use.3. Using Tiaoshen Dingxuan soup and Betahistine mesilate tablets treat cervcal spondylosis of vertebral artery type (blood deficiency type), no significant toxicity and allergies during clinical observation, indicating that the treatment is safe and effective, can be clinical. Suggested that clinical treatment2weeks for one period of treatment.